Dr. Somnath Chatterjee has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Somnath Chatterjee, on behalf of himself and the broader promoter group of Suraksha Diagnostic Limited, has submitted a declaration to BSE and NSE under Regulation 31(4) of SEBI's Takeover Regulations. The filing confirms that the promoters have not created any new encumbrances (pledges) on their shares beyond what was already disclosed during the financial year ended 31 March 2026. The disclosure includes detailed annexures listing individual promoter group members (such as family members of Dr. Somnath Chatterjee, Ritu Mittal, and Satish Kumar Verma) as well as a large number of entity names forming the promoter group, including various LLPs and private companies. This is a routine regulatory filing confirming the status of share pledges.
This is a routine compliance filing with no new or concerning developments. The nil-additional-encumbrance declaration is a positive signal indicating promoters have not taken on fresh debt against their shares. It should have no material negative impact on the stock.